COPENHAGEN, Denmark -- (BUSINESS WIRE) --
Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200421005973/en/
A milestone achievement
The development of the first stand-alone dose sparing polio vaccine is a milestone for the significant investment and innovation in the Danish based vaccine production. “The WHO prequalification is an acknowledgement of our continued investment which enables AJ Vaccines to serve the growing demand for effective polio vaccines and we hereby open a new chapter in the company’s continued journey to serve the Danish population and a growing number of people globally”, says Mr. Abdulaziz Hamad Aljomaih, founding principal investor in AJ Vaccines.
A tribute to dedicated employees
The achievement of the WHO prequalification is a tribute to the employees for their dedication and contribution to a comprehensive review of production process and quality control procedures, independent laboratory testing, assessment of files and a site audit of manufacturing facilities carried out jointly between the WHO and Danish Medicines Agency in 2019. “The prequalification is a recognition of our dedicated employees’ competencies and embodies the essence of our company’s vision, striving for a world free of serious diseases across generations”, says Dr. Tabassum Khan, Chairman of AJ Vaccines.
Significant investments
The Picovax® development project was supported by the Bill & Melinda Gates Foundation. “Since our take over in 2017, we have invested significantly in the strategic expansion of our production facilities and recruitment of 200 new employees to secure AJ Vaccines’ position as a significant player in the vaccine market, contributing to the important strategic global goal for the eradication of polio”, says Jesper Helmuth Larsen, CEO of AJ Vaccines.
The new vaccine will play a key role in the Global Polio Eradication Initiative (GPEI)
The new Inactivated Polio Vaccine, Picovax®, is indicated for active immunization against poliomyelitis by primary vaccination of infants from the age of six weeks, and for revaccination of infants, children and adolescents. The dose sparing IPV is shown to provide protection comparable to that provided by other inactivated polio vaccines currently available. “The dose sparing technology secures a much-needed increase in supply, helping to meet the increasing demand for inactivated polio vaccines to support the Global Polio Eradication Initiative”, concludes Jérôme Cabannes, COO AJ Vaccines.
新汉普影视 差异化定制满足客户多元化需求
Beyond Now的数字商业平台驱动
Northern Data宣布SBI成为公司新的战略股东
RevBits在其 Endpoint Security
hpv 终于奇迹般的转阴了
NetApp 将数据优化和企业级数据服务引入云端
GSMA MWC19巴塞罗那圆满落下帷幕
第22届中国国际高新技术成果交易会圆满闭幕
强势发力|2022北京建筑业博览会第一波采购团来
广饶县大王镇中心小学举行“家长开放日”活动
【家园共育】高新区小营中心幼儿园大班级部讲
Sims Limited 任命董事会成员
CSC与NetDiligence携手帮助减轻网络安全风险
BAI Communications携手Mavenir
Celsius Network启动财务重组,旨在稳定业
全球领导人讨论净零排放——自8月11日(周三)
Johns Manville宣布Katie Albery
ROSEN提醒Nikola Corporation投资者
汉阳区启动“老带小、小促老”,老少携手参与
斯伦贝谢宣布2022年第三季度业绩
Gravity正式在Nintendo Switch
ABLIC Inc.推出S-35710/20唤醒计时器IC
EIG签署协议,将以15.92亿美元收购APLNG 10%
滨城区第一小学教育集团举办班主任工作论坛